Tag Archive for: Biovac Institute

Sisipho Ntsabo
, ,

Biovac To Produce Covid-19 Vaccine in Africa

BioNTech and Pfizer have announced that they reached a deal with Biovac to produce Covid-19 for the African Union (AU) countries beginning in 2022. Biovac is a bio-pharmaceutical company that was established with the South African government as a partnership for local vaccine manufacturing capability. Under this agreement, 100 million doses are expected to be produced annually for the AU countries.

In an MoneyWeb’s interview with the CEO of Biovac, Dr Morena Makhoana states that this is a historical moment for Africa as this is the first mRNA technology transfer on the continent. Pfizer has committed about 30 million doses of the Pfizer vaccine before the Biovac-Pfizer agreement.

Biovac CEO states, “The deal is to “fill and finish” the vaccine, the final stages of manufacturing where the product is processed and put into vials. It does not cover the complicated processes of mRNA drug substance production, which Pfizer and BioNTech will do at their own facilities in Europe”.

Pfizer released a press release in which the full statement of the Biovac and Pfizer-Biotech deal was extensively discussed. In the technicality of the manufacturing of the vaccine in Africa, Pfizer writes, “Biovac will perform manufacturing and distribution activities within Pfizer’s and BioNTech’s global COVID-19 vaccine supply chain and manufacturing network, which will now span three continents and include more than 20 manufacturing facilities. To facilitate Biovac’s involvement in the process, technical transfer, on-site development and equipment installation activities will begin immediately.”

We can expect the Biovac’s integration into the vaccine supply chain by the end of 2021, while the manufacturing of finished doses is scheduled to star in 2022. Once full operation capacity is reached, the annual production is set to exceed 100 million finished doses distributed within the 55 states of the AU.

Pfizer Chairman and CEO, Albert Bourla wrote, “Our latest collaboration with Biovac is a shining example of the tireless work being done, in this instance to benefit Africa. We will continue to explore and pursue opportunities to bring new partners into our supply chain network, including in Latin America, to further accelerate access of COVID-19 vaccines.”

This is good news for the continent of Africa. Currently experiencing the third-wave and a hampered rollout out, things are looking up as Senegal joins likes of Egypt, Morocco, and South Africa in the list of African countries that have successfully secured the rights to produce the jabs.

South Africa will be a great destination for investment, and we are proud to offer services for Immigration and Relocation services into Cape Town, Durban, Johannesburg. Please contact us for further information.

Have a look at the brief overview, housing, school and immigration information about South Africa on our location’s website: https://www.relocationafrica.com/locations/south-africa/

 

 

 

Andrew Stegmann
,

South Africa May Be First in Region to Produce COVID-19 Vaccine

South Africa may sign a deal to help produce a Covid-19 vaccine, potentially boosting access to immunisation on a continent with limited manufacturing capacity.

The Coalition for Epidemic Preparedness Innovations, a global organisation funding vaccine development, is considering the Cape Town-based Biovac Institute as a fill-finish site, according to Helen Rees, the chair of the organisation’s Scientific Advisory Board. The state vaccine company is one of few in the country that has the capacity to package doses into sterile dispensers if clinical trials are successful.

“What we are looking at is partnerships,” Morena Makhoana, Biovac’s chief executive officer, said in response to questions. “Once that is signed, we will be able to make an announcement.”

A manufacturing agreement will “put Africa on a similar path to other continents, much like the clinical trials are doing,” he said.

South Africa is the only country in Africa that hosts several clinical studies. It has 2,000 people in the AstraZeneca Plc and University of Oxford vaccine trial, while Novavax Inc. announced earlier this month it’s starting a Phase 2b clinical trial. One-fifth of the 60,000 volunteers expected to enroll worldwide in Johnson & Johnson’s Covid-19 vaccine trial will be in South Africa, said Glenda Gray, the chief executive officer of the South African Medical Research Council.

“Covid-19 has really thrown into focus that we have very limited capacity for vaccine manufacturing across the African continent, even in countries like South Africa,” said Rees. “But there’s tremendous interest and we need to have more countries being able to manufacture vaccines.”

 

For information as to how Relocation Africa can help you with your Mobility, Immigration, Research, Remuneration, and Expat Tax needs, email info@relocationafrica.com, or call us on +27 21 763 4240.

Sources: [1], [2]. Image sources: [1], [2].